Shiga Toxin A Subunit Polypeptides Site-Specific Conjugation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for conjugating biological molecules, such as Shiga toxin effector polypeptides, face challenges in controlling site specificity, achieving homogeneity, and ensuring cost-effectiveness, which are crucial for therapeutic and diagnostic applications due to issues like heterogeneous mixtures and inefficient purification processes.
Innovation Solution
The development of Shiga toxin A Subunit effector polypeptides with unique site-specific amino acid residues allows for controlled, site-specific conjugation of molecules, enabling precise delivery and altering properties of cell-targeting molecules, including the use of ectopic amino acid residues for linking cargos or altering agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If traditional conjugation methods are used to link biological molecules, then conjugation can be achieved, but site specificity is poor and heterogeneous mixtures are produced
Solution Approach 1:
The patent introduces unique amino acid residues (such as non-natural amino acids with distinctive side chains) at specific positions within the Shiga toxin A subunit polypeptide sequence. These localized modifications create distinct chemical properties at specific sites, enabling site-specific conjugation while maintaining overall polypeptide homogeneity. The unique residues serve as predetermined attachment points that differentiate specific locations without affecting the global structure.
Solution Approach 2:
The patent employs chemical reactions that exploit specific functional groups introduced by unique amino acid residues (such as azide, alkyne, or other reactive side chains) to form covalent bonds with cargo molecules. By changing the chemical parameters at specific residues while keeping the rest of the polypeptide unchanged, the invention achieves site-specific conjugation with high precision and homogeneous product composition.
2Ease of manufacture
If traditional conjugation methods are used, then conjugation can be achieved, but purification is inefficient and costs increase
Solution Approach 1:
The patent incorporates unique amino acid residues with distinctive chemical properties (such as biotin, fluorescent tags, or other affinity handles) at predetermined positions during polypeptide synthesis. These preliminary modifications enable subsequent selective purification through affinity chromatography or other specific binding methods, dramatically improving purification efficiency and reducing costs by eliminating the need for complex separation procedures to resolve heterogeneous mixtures.
3Stability of the object's composition
If site-specific amino acid residues are introduced for controlled conjugation, then homogeneous molecules are produced, but the complexity of the conjugation process increases
Solution Approach 1:
The patent uses unique amino acid residues as intermediary elements that facilitate conjugation through their distinctive chemical properties. These intermediaries (such as non-natural amino acids with reactive side chains) act as built-in handles that simplify the conjugation process by providing predetermined, chemically selective attachment points, reducing the need for complex external reagents or multi-step procedures while maintaining homogeneous product composition.
Data Source
AI summary
The present invention provides Shiga toxin A Subunit derived polypeptides, scaffolds, and cell-targeting molecules comprising amino acid substitutions which equip the molecules with site-specific positions (and often unique amino acid residues in the molecule) for linking other molecules while retaining Shiga toxin function(s), such as, e.g., efficient intracellular routing and/or potent cytotoxicity. The present invention also provides cell-targeting molecules, and/or components thereof, which comprise site-specific positions for linking other molecules, such as, e.g., agents that alters a property of the cell-targeting molecule or a cargo for delivery. Certain molecules comprising a polypeptide of the present invention exhibit reduced immunogenicity and/or are well-tolerated by mammals. The cell-targeting molecules of the present invention, and compositions thereof, have uses, e.g., for the selective delivery of cargos to target-expressing cells and as diagnostic and/or therapeutic molecules for the treatment of a variety of diseases, disorders, and conditions, which include genetic disorders, genetic predispositions, infections, cancers, tumors, growth abnormalities, and/or immune disorders.